|Alexza Pharmaceuticals Inc.|
2091 Stierlin Court
United States - Map
Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The companys product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Its lead program includes ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The companys product candidates include AZ-002 (Staccato alprazolam) for the treatment of acute repetitive seizures. It has a collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.
|Mr. Thomas B. King ,
Chief Exec. Officer, Pres and Director
|Dr. James V. Cassella Ph.D.,
Chief Scientific Officer and Exec. VP of R&D
|Mr. Michael J. Simms ,
Sr. VP of Operations & Manufacturing
|Mr. Mark K. Oki CPA,
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
|Mr. Robert A. Lippe ,
Chief Operations Officer and Exec. VP of Operations
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|